| 摘要 |
The invention relates to a process for the preparation of an injectable chondroitin polysulfate, which is characterized in that A crude chondroitin polysulfate is depolymerized oxidatively, B the depolymerized chondroitin polysulfate is bleached, if necessary, with peracetic acid, C the product obtained after A or B is subjected once or twice to precipitation with methanol and/or ultrafiltration for fractionation with respect to molecular weight, D the product obtained after C is demineralized, if necessary, with cation exchangers, and E the product obtained after C or D is decolorized, if necessary, with active charcoal. The invention furthermore relates to a chondroitin polysulfate which can be prepared by the above process. The invention also relates to a chondroitin polysulfate with an acute toxicity (LD50), on intravenous administration, of >3,500 mg/kg in NMRI mice, of >3,000 mg/kg in Wistar rats, of >1,000 mg/kg in cats and of >1,000 mg/kg in dogs. Finally, the invention relates to a pharmaceutical composition for human and veterinary medicine, characterized in that it contains a chondroitin polysulfate which can be prepared according to the above process of a chondroitin polysulfate with the above characteristics.
|
